Friday the 13th proved lucky for Merck & Co., Inc. ’s Keytruda (pembrolizumab), which claimed an approval bringing the immuno-oncologic into the triple negative breast cancer treatment space. The US
IN VITRO DIAGNOSTICS Alliances AEterna Zentaris Inc. Armune BioScience Inc. Armune BioScience Inc. granted AEterna Zentaris Inc. rights to sell its Apifiny prostate cancer diagnostic to desi